Loading organizations...
§ Private Profile · Ayer, MA, USA
Biotechnology company developing medical devices and gene therapies for precision drug delivery to CNS disorders
Founded in 2010 by PJ Anand, Adam Fleisher, William Olbricht, and David Donabedian, Alcyone Lifesciences is a Lowell, Massachusetts biotechnology company developing precision drug delivery systems for severe central nervous system disorders. The privately held enterprise engineers implantable microcatheters designed to accurately route molecular therapies to specific targets within the brain and spinal cord. Operating with 10 to 50 employees, the firm secured capital from investors like RTW Investments and Edgar Jannotta Jr., including a $4 million Series B in 2014 and a $23 million round in 2021. In 2022, the organization entered a strategic agreement with Biogen, receiving a $10 million upfront payment to develop an implantable device for delivering antisense oligonucleotides. To combine its delivery platforms with proprietary gene therapies, the company expanded in 2020 by launching a successor entity known as Alcyone Therapeutics.
Alcyone Lifesciences has raised $5.8M across 2 funding rounds.
Alcyone Lifesciences has raised $5.8M in total across 2 funding rounds.
Alcyone Lifesciences has raised $5.8M across 2 funding rounds. Most recently, it raised $4.0M Series B in January 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 15, 2014 | $4M Series B | Edgar D. Jannotta, JR. | Harbor Light Capital | Announced |
| Mar 28, 2012 | $1.8M Venture Round | — | — | Announced |
Alcyone Lifesciences has raised $5.8M in total across 2 funding rounds.
Alcyone Lifesciences's investors include Edgar D. Jannotta, Jr., Harbor Light Capital.